NCT05367401View on ClinicalTrials.gov

A Study of Sabatolimab and Magrolimab-based Treatment in AML or Higher Risk MDS Participants

PHASE1/PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

December 20, 2024

Primary Completion Date

October 26, 2029

Study Completion Date

October 26, 2029

Conditions
Myelodysplastic SyndromesAcute Myeloid Leukemia
Interventions
DRUG

Sabatolimab

Solution for intravenous infusion

DRUG

Magrolimab

Solution for intravenous infusion

DRUG

Azacitidine

Solution for subcutaneous injection or intravenous infusion

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY